Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY; Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY.
Urol Oncol. 2023 Oct;41(10):395-397. doi: 10.1016/j.urolonc.2023.08.020. Epub 2023 Oct 11.
The advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in treating patients with metastatic urothelial cancer. Yet, there are inherent challenges in utilizing these therapies, including the management of treatment-related toxicities. In this special Urologic Oncology: Seminars and Original Investigations issue, we review the latest developments and discuss insights into future research needs.
靶向治疗、免疫治疗的进展以及最近抗体药物偶联物（ADC）的出现，预示着转移性尿路上皮癌治疗可能出现范式转变。然而，在利用这些疗法时存在固有挑战，包括治疗相关毒性的管理。在本期《泌尿肿瘤学：研讨会和原始研究》特刊中，我们回顾了最新进展，并探讨了对未来研究需求的见解。
